Quest Diagnostics (Quest Diagnostics) Risk Assessment

View and export this data going back to 1996. Start your Free Trial

What is Quest Diagnostics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Quest Diagnostics is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Quest Diagnostics's Risk Assessment

For the Diagnostics & Research subindustry, Quest Diagnostics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quest Diagnostics's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Quest Diagnostics's Risk Assessment falls into.

Quest Diagnostics (NYSE:DGX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Quest Diagnostics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Quest Diagnostics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Quest Diagnostics (Quest Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (NYSE:DGX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

QDI:Germany

Address

500 Plaza Drive, Secaucus, NJ, USA, 07094

Website

https://www.questdiagnostics.com

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Executives

Luis Diaz	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138
Michael E Prevoznik	officer: Corp VP, Legal & Compliance	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Catherine T. Doherty	officer: SVP, Physician Services Bus.	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Timothy M Ring	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Mark E Delaney	officer: SVP & Chief Commercial Officer	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Mark A Gardner	officer: SVP of Molecular Gen & Oncol	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Patrick Plewman	officer: SVP for Diagnostic Services	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Karthik Kuppusamy	officer: SVP, Clinical Solutions	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Michael J Deppe	officer: VP, Corp. Controller & CAO	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094
Samer Abdul Samad	officer: Executive Vice President & CFO	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stephen H Rusckowski	director, officer: President and CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Tracey Doi	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Gail R Wilensky	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Mark Guinan	officer: Senior Vice President & CFO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel Stanzione	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094